{"id":732894,"date":"2023-02-21T07:15:29","date_gmt":"2023-02-21T12:15:29","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-present-at-the-h-c-wainwright-cell-therapy-virtual-conference\/"},"modified":"2023-02-21T07:15:29","modified_gmt":"2023-02-21T12:15:29","slug":"in8bio-to-present-at-the-h-c-wainwright-cell-therapy-virtual-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-present-at-the-h-c-wainwright-cell-therapy-virtual-conference\/","title":{"rendered":"IN8bio to Present at the H.C. Wainwright Cell Therapy Virtual Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">NEW YORK, Feb.  21, 2023  (GLOBE NEWSWIRE) &#8212; IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will present a fireside chat at the H.C. Wainwright Cell Therapy Virtual Conference on Tuesday, February 28, 2023 at 1:30 pm ET.<\/p>\n<p>The H.C. Wainwright presentation will be available live and as a replay on IN8bio\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=thlnU4unzKvrGBLL5CxJeUhgxzVfP63tS1ukbaUYJ1f3ss9G6tsh8xmi6I41dz32ZhX3YPaaCCq8K4Xb37WFdlNNYlZKes4p1Zaud4JAyJg=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/bit.ly\/3F1WEaQ<\/a>.<\/p>\n<p>\n        <strong>About IN8bio<\/strong><br \/>\n        <br \/>IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. IN8bio\u2019s DeltEx platform employs allogeneic, autologous, iPSC and genetically modified approaches to develop cell therapies, designed to effectively identify and eradicate tumor cells.<\/p>\n<p>IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma and INB-100 for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation. IN8bio is initiating INB-400, a company-sponsored Phase 2 clinical trial in newly diagnosed glioblastoma following IND clearance in late 2022. IN8bio also has a broad portfolio of preclinical programs focused on addressing other solid tumor types. For more information about IN8bio and its programs, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FTf-FFsSFBGbFFmMBhTI9mOpxZoOowTDQdH1W_6ElTZJf28-r7t8IWut03-QvwWj_mpSGIS4KESLZv0sQZYqWQ==\" rel=\"nofollow noopener\" target=\"_blank\">www.IN8bio.com<\/a>.<\/p>\n<p>\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>IN8bio, Inc.<br \/>Patrick McCall<br \/>+ 1 646.600.6GDT (6438)<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pC_rMZvRI1aSm0QL3_aRKa3ojYk5f0sIBTRgQUxCcRhTM_ZBDoyjRo9ckrN5N9aKvj8AjcLRazpPrPOW-onqqA==\" rel=\"nofollow noopener\" target=\"_blank\"><u>info@IN8bio.com<\/u><\/a><\/p>\n<p>\n        <strong>Investors &amp; Media Contact: <\/strong><br \/>\n        <br \/>Argot Partners<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=58LgbLAcinAFZPORGrXqXwDQzVijbWuqTTs5rqXrF0sKFkRBhf8GjlMEv_7SIGfYu9zUHyYzXACytJPSs3FECNj2j1rQHzZPaswr6C2lEhg=\" rel=\"nofollow noopener\" target=\"_blank\">IN8bio@argotpartners.com<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MjExNyM1NDE3Mjc0IzIxMjMwMDY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MzNmOGRlN2QtY2U0Zi00ZDczLTg3ZTMtN2FmOTk3MGI2NGZhLTExMzQ1Nzc=\/tiny\/IN8bio-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Feb. 21, 2023 (GLOBE NEWSWIRE) &#8212; IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will present a fireside chat at the H.C. Wainwright Cell Therapy Virtual Conference on Tuesday, February 28, 2023 at 1:30 pm ET. The H.C. Wainwright presentation will be available live and as a replay on IN8bio\u2019s website at https:\/\/bit.ly\/3F1WEaQ. About IN8bio IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-present-at-the-h-c-wainwright-cell-therapy-virtual-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;IN8bio to Present at the H.C. Wainwright Cell Therapy Virtual Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-732894","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>IN8bio to Present at the H.C. Wainwright Cell Therapy Virtual Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-present-at-the-h-c-wainwright-cell-therapy-virtual-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IN8bio to Present at the H.C. Wainwright Cell Therapy Virtual Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Feb. 21, 2023 (GLOBE NEWSWIRE) &#8212; IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will present a fireside chat at the H.C. Wainwright Cell Therapy Virtual Conference on Tuesday, February 28, 2023 at 1:30 pm ET. The H.C. Wainwright presentation will be available live and as a replay on IN8bio\u2019s website at https:\/\/bit.ly\/3F1WEaQ. About IN8bio IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. &hellip; Continue reading &quot;IN8bio to Present at the H.C. Wainwright Cell Therapy Virtual Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-present-at-the-h-c-wainwright-cell-therapy-virtual-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-21T12:15:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MjExNyM1NDE3Mjc0IzIxMjMwMDY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-to-present-at-the-h-c-wainwright-cell-therapy-virtual-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-to-present-at-the-h-c-wainwright-cell-therapy-virtual-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"IN8bio to Present at the H.C. Wainwright Cell Therapy Virtual Conference\",\"datePublished\":\"2023-02-21T12:15:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-to-present-at-the-h-c-wainwright-cell-therapy-virtual-conference\\\/\"},\"wordCount\":277,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-to-present-at-the-h-c-wainwright-cell-therapy-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc1MjExNyM1NDE3Mjc0IzIxMjMwMDY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-to-present-at-the-h-c-wainwright-cell-therapy-virtual-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-to-present-at-the-h-c-wainwright-cell-therapy-virtual-conference\\\/\",\"name\":\"IN8bio to Present at the H.C. Wainwright Cell Therapy Virtual Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-to-present-at-the-h-c-wainwright-cell-therapy-virtual-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-to-present-at-the-h-c-wainwright-cell-therapy-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc1MjExNyM1NDE3Mjc0IzIxMjMwMDY=\",\"datePublished\":\"2023-02-21T12:15:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-to-present-at-the-h-c-wainwright-cell-therapy-virtual-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-to-present-at-the-h-c-wainwright-cell-therapy-virtual-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-to-present-at-the-h-c-wainwright-cell-therapy-virtual-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc1MjExNyM1NDE3Mjc0IzIxMjMwMDY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc1MjExNyM1NDE3Mjc0IzIxMjMwMDY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-to-present-at-the-h-c-wainwright-cell-therapy-virtual-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IN8bio to Present at the H.C. Wainwright Cell Therapy Virtual Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IN8bio to Present at the H.C. Wainwright Cell Therapy Virtual Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-present-at-the-h-c-wainwright-cell-therapy-virtual-conference\/","og_locale":"en_US","og_type":"article","og_title":"IN8bio to Present at the H.C. Wainwright Cell Therapy Virtual Conference - Market Newsdesk","og_description":"NEW YORK, Feb. 21, 2023 (GLOBE NEWSWIRE) &#8212; IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will present a fireside chat at the H.C. Wainwright Cell Therapy Virtual Conference on Tuesday, February 28, 2023 at 1:30 pm ET. The H.C. Wainwright presentation will be available live and as a replay on IN8bio\u2019s website at https:\/\/bit.ly\/3F1WEaQ. About IN8bio IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. &hellip; Continue reading \"IN8bio to Present at the H.C. Wainwright Cell Therapy Virtual Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-present-at-the-h-c-wainwright-cell-therapy-virtual-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-02-21T12:15:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MjExNyM1NDE3Mjc0IzIxMjMwMDY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-present-at-the-h-c-wainwright-cell-therapy-virtual-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-present-at-the-h-c-wainwright-cell-therapy-virtual-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"IN8bio to Present at the H.C. Wainwright Cell Therapy Virtual Conference","datePublished":"2023-02-21T12:15:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-present-at-the-h-c-wainwright-cell-therapy-virtual-conference\/"},"wordCount":277,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-present-at-the-h-c-wainwright-cell-therapy-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MjExNyM1NDE3Mjc0IzIxMjMwMDY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-present-at-the-h-c-wainwright-cell-therapy-virtual-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-present-at-the-h-c-wainwright-cell-therapy-virtual-conference\/","name":"IN8bio to Present at the H.C. Wainwright Cell Therapy Virtual Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-present-at-the-h-c-wainwright-cell-therapy-virtual-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-present-at-the-h-c-wainwright-cell-therapy-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MjExNyM1NDE3Mjc0IzIxMjMwMDY=","datePublished":"2023-02-21T12:15:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-present-at-the-h-c-wainwright-cell-therapy-virtual-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-present-at-the-h-c-wainwright-cell-therapy-virtual-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-present-at-the-h-c-wainwright-cell-therapy-virtual-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MjExNyM1NDE3Mjc0IzIxMjMwMDY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MjExNyM1NDE3Mjc0IzIxMjMwMDY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-present-at-the-h-c-wainwright-cell-therapy-virtual-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"IN8bio to Present at the H.C. Wainwright Cell Therapy Virtual Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/732894","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=732894"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/732894\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=732894"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=732894"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=732894"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}